171 related articles for article (PubMed ID: 19656128)
1. Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients.
Kamar N; Milioto O; Puissant-Lubrano B; Esposito L; Pierre MC; Mohamed AO; Lavayssière L; Cointault O; Ribes D; Cardeau I; Nogier MB; Durand D; Abbal M; Blancher A; Rostaing L
Am J Transplant; 2010 Jan; 10(1):89-98. PubMed ID: 19656128
[TBL] [Abstract][Full Text] [Related]
2. Rituximab Therapy and Infection Risk in Pediatric Renal Transplant Patients.
Gulleroglu K; Baskin E; Moray G; Ozdemir H; Arslan H; Haberal M
Exp Clin Transplant; 2016 Apr; 14(2):172-5. PubMed ID: 26742572
[TBL] [Abstract][Full Text] [Related]
3. Combined use of rituximab and plasmapheresis pre-transplant increases post-transplant infections in renal transplant recipients with basiliximab induction therapy.
Chung BH; Yun JT; Ha SE; Kim JI; Moon IS; Choi BS; Park CW; Kim YS; Yang CW
Transpl Infect Dis; 2013 Dec; 15(6):559-68. PubMed ID: 24011062
[TBL] [Abstract][Full Text] [Related]
4. Is rituximab safe to use in kidney transplant patients?
Jordan SC; Glotz D
Am J Transplant; 2010 Jan; 10(1):8-9. PubMed ID: 19958329
[No Abstract] [Full Text] [Related]
5. Comparison of daclizumab, an interleukin 2 receptor antibody, to anti-thymocyte globulin-Fresenius induction therapy in kidney transplantation.
Abou-Jaoude MM; Ghantous I; Almawi WY
Mol Immunol; 2003 Jul; 39(17-18):1083-8. PubMed ID: 12835081
[TBL] [Abstract][Full Text] [Related]
6. Rituximab induction therapy in highly sensitized kidney transplant recipients.
Yin H; Wan H; Hu XP; Li XB; Wang W; Liu H; Ren L; Zhang XD
Chin Med J (Engl); 2011 Jul; 124(13):1928-32. PubMed ID: 22088448
[TBL] [Abstract][Full Text] [Related]
7. Secular Trends in Infection-Related Mortality after Kidney Transplantation.
Kinnunen S; Karhapää P; Juutilainen A; Finne P; Helanterä I
Clin J Am Soc Nephrol; 2018 May; 13(5):755-762. PubMed ID: 29622669
[TBL] [Abstract][Full Text] [Related]
8. Incidence of Infectious Disease and Malignancies After Rituximab Therapy in Kidney Transplant Recipients: Results From a Cohort in Germany.
Schrezenmeier E; Budde K; Staeck O; Lehner L; Duerr M; Khadzhynov D; Dörner T; Halleck F
Transplant Proc; 2017 Dec; 49(10):2269-2273. PubMed ID: 29198659
[TBL] [Abstract][Full Text] [Related]
9. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody.
Peleg AY; Husain S; Kwak EJ; Silveira FP; Ndirangu M; Tran J; Shutt KA; Shapiro R; Thai N; Abu-Elmagd K; McCurry KR; Marcos A; Paterson DL
Clin Infect Dis; 2007 Jan; 44(2):204-12. PubMed ID: 17173218
[TBL] [Abstract][Full Text] [Related]
10. Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin.
Kahwaji J; Sinha A; Toyoda M; Ge S; Reinsmoen N; Cao K; Lai CH; Villicana R; Peng A; Jordan S; Vo A
Clin J Am Soc Nephrol; 2011 Dec; 6(12):2894-900. PubMed ID: 22157713
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus infection and rituximab therapy after renal transplantation.
Fabrizi F; Martin P; Elli A; Montagnino G; Banfi G; Passerini P; Campise MR; Tarantino A; Ponticelli C
Int J Artif Organs; 2007 May; 30(5):445-9. PubMed ID: 17551909
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
13. Rituximab may not lead to increased infection rates in transplant recipients.
Drage M; Hadjianastassiou V; Dorling A; Mamode N
Am J Transplant; 2010 Dec; 10(12):2723-4. PubMed ID: 21114650
[No Abstract] [Full Text] [Related]
14. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation.
Tydén G; Genberg H; Tollemar J; Ekberg H; Persson NH; Tufveson G; Wadström J; Gäbel M; Mjörnstedt L
Transplantation; 2009 May; 87(9):1325-9. PubMed ID: 19424032
[TBL] [Abstract][Full Text] [Related]
15. Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis.
Klein K; Süsal C; Schäfer SM; Becker LE; Beimler J; Schwenger V; Zeier M; Schemmer P; Macher-Goeppinger S; Scherer S; Opelz G; Morath C
Atheroscler Suppl; 2013 Jan; 14(1):199-202. PubMed ID: 23357165
[TBL] [Abstract][Full Text] [Related]
16. Is rituximab safe to use in kidney transplant patients?
Tydén G; Mjornstedt L; Ekberg H; Tufveson G
Am J Transplant; 2010 Aug; 10(8):1949; author reply 1950. PubMed ID: 20659100
[No Abstract] [Full Text] [Related]
17. Rabbit antithymocyte globulin versus basiliximab in renal transplantation.
Brennan DC; Daller JA; Lake KD; Cibrik D; Del Castillo D;
N Engl J Med; 2006 Nov; 355(19):1967-77. PubMed ID: 17093248
[TBL] [Abstract][Full Text] [Related]
18. Infectious complications in kidney transplant: a Lebanese perspective.
Abou-Jaoude MM; Nawfal N; Shaheen J; Daoud Z; Almawi WY
Exp Clin Transplant; 2010 Jun; 8(2):136-41. PubMed ID: 20565370
[TBL] [Abstract][Full Text] [Related]
19. Rituximab as induction therapy after renal transplantation: a randomized, double-blind, placebo-controlled study of efficacy and safety.
van den Hoogen MW; Kamburova EG; Baas MC; Steenbergen EJ; Florquin S; M Koenen HJ; Joosten I; Hilbrands LB
Am J Transplant; 2015 Feb; 15(2):407-16. PubMed ID: 25612493
[TBL] [Abstract][Full Text] [Related]
20. Highly Sensitized Patients: Miami Transplant Institute Experience.
Mattiazzi AD; Centeno A; Amador A; Fernandez-Bango C; Scowby CD; O'Rourke M; Hill-Matthie T; Patel R; Barrios F; Ruiz P; Chen L; Saghesima J; Ciancio G; Burke GW; Goldstein M; Chandar J; Contreras G; Roth D; Kupin W; Guerra G; Vianna R
Clin Transpl; 2014; ():171-8. PubMed ID: 26281142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
